EDITORIAL

Vol. 26 No. 4 (2016): Psychiatry and Clinical Psychopharmacology

Comment on FDA’s Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

Main Article Content

Reji Thomas
Mesut Cetin
Glen B. Baker
Serdar M. Dursun

Abstract

-

Article Details